MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Home・Akciju saraksts・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Slēgts

3.95 -1

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.77

Max

3.98

Galvenie mērījumi
By Trading Economics
Ienākumi	466K -27M
Pārdošana	2M 15M
Peļņas marža	-178.834
Darbinieki	141
EBITDA	-2M -29M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+280.05% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	2.1M 231M
Iepriekšējā atvēršanas cena	4.95
Iepriekšējā slēgšanas cena	3.95

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

3.17 / 3.4644 Atbalsts un pretestība

Voyager Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 2. apr. 17:11 UTC

Galvenie tirgus virzītāji

Galvenie ziņu notikumi

Home Depot Shares Hit 52-Week Low as Iran War Threatens Housing Rebound

2026. g. 2. apr. 17:10 UTC

Galvenie ziņu notikumi

ECB's Next Move Likely a Rate Rise, But Timing Unclear Amid Iran War, Villeroy Says

2026. g. 2. apr. 23:47 UTC

Tirgus saruna

Galvenie ziņu notikumi

Nikkei Might Rise After Thursday's Selloffs -- Market Talk

2026. g. 2. apr. 21:05 UTC

Iegādes, apvienošanās, pārņemšana

Starbucks: Under the Terms of the Agreement, Funds Managed by Boyu Cap Now Hold a 60% Stake in Starbucks China Retail Ops >SBUX

2026. g. 2. apr. 21:05 UTC

Iegādes, apvienošanās, pārņemšana

Starbucks: Retains 40% Ownership Interest and Continues to Own and License the Brand and Intellectual Property to JV >SBUX

2026. g. 2. apr. 21:05 UTC

Iegādes, apvienošanās, pārņemšana

Starbucks: Joint Venture Is Designed to Enhance Starbucks Ability to Expand Footprint, Deepen Local Relevance >SBUX

2026. g. 2. apr. 21:05 UTC

Iegādes, apvienošanās, pārņemšana

Starbucks and Boyu Cap: Finalize Joint Venture to Accelerate Long-Term Growth in China

2026. g. 2. apr. 21:01 UTC

Galvenie ziņu notikumi

Investors Waver after Trump Speech on Iran, Ending Two-Day Surge in Stocks -- WSJ

2026. g. 2. apr. 20:59 UTC

Iegādes, apvienošanās, pārņemšana

Starbucks and Boyu Capital Finalize China JV

2026. g. 2. apr. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 2. apr. 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 2. apr. 20:41 UTC

Peļņas

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2026. g. 2. apr. 20:32 UTC

Tirgus saruna

Higher Gas Prices Intensify K-Shaped Economy -- Market Talk

2026. g. 2. apr. 20:30 UTC

Iegādes, apvienošanās, pārņemšana

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2026. g. 2. apr. 20:09 UTC

Tirgus saruna

Eli Lilly On More Equal Footing With Rival With Weight-Loss Pill -- Market Talk

2026. g. 2. apr. 20:01 UTC

Iegādes, apvienošanās, pārņemšana

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2026. g. 2. apr. 19:46 UTC

Tirgus saruna

Is Oil the New GameStop? -- Market Talk

2026. g. 2. apr. 19:35 UTC

Tirgus saruna

U.S. Natural Gas Falls As Storage Injection Season Gets Under Way -- Market Talk

2026. g. 2. apr. 19:29 UTC

Iegādes, apvienošanās, pārņemšana

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2026. g. 2. apr. 19:24 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Jump Ahead of Long Weekend -- Market Talk

2026. g. 2. apr. 19:20 UTC

Tirgus saruna

Nike Has Yet to Show That a Turnaround is on Horizon -- Market Talk

2026. g. 2. apr. 19:01 UTC

Iegādes, apvienošanās, pārņemšana

Union Pacific: ATDA Agreement to Guarantee Jobs for Life for Union Employees After Norfolk Southern Deal

2026. g. 2. apr. 19:00 UTC

Iegādes, apvienošanās, pārņemšana

Union Pacific: Agreement Reached With American Train Dispatchers Association

2026. g. 2. apr. 18:24 UTC

Iegādes, apvienošanās, pārņemšana

Globalstar Stock Rises on Amazon Deal Report. Why Apple Could Scuttle the Launch. -- Barrons.com

2026. g. 2. apr. 17:44 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Supply Squeeze Puts Refiners in a Quandary -- Market Talk

2026. g. 2. apr. 17:32 UTC

Galvenie ziņu notikumi

Amazon to Boost Fuel Surcharges on Third-Party Sellers as Costs Rise -- Barrons.com

2026. g. 2. apr. 17:26 UTC

Peļņas

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2026. g. 2. apr. 17:17 UTC

Tirgus saruna

Shares of Canadian Exports Heading to U.S. Continues to Slide -- Market Talk

2026. g. 2. apr. 17:09 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Holds Gains After Trump Speech Disappointed Market -- Market Talk

2026. g. 2. apr. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Voyager Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

280.05% augšup

Prognoze 12 mēnešiem

Vidējais 14.67 USD 280.05%

Augstākais 25 USD

Zemākais 8 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Voyager Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 8 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Voyager Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

3.17 / 3.4644Atbalsts un pretestība

Recent bearish events outweigh bullish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.